research

Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Neumora Therapeutics held its Q4 2025 earnings call on March 30, 2026, led by CEO Paul Berns and CFO Mike Milligan, detailing financial results and corporate strategy updates. The company emphasized progress in its neuroscience pipeline, with Chief Scientific Officer Nick Brandon highlighting advancements in precision psychiatry and brain disorder treatments. CFO Mike Milligan reported year-end financials, noting cash runway and funding allocations for R&D, though specific figures were not detailed in the transcript excerpt. Analysts from firms like RBC Capital and William Blair questioned clinical trial timelines and regulatory pathways, signaling investor focus on execution risks. Forward-looking statements were issued with caution, citing SEC filings for risk factors, reflecting uncertainty in drug development and market conditions.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.16K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call March 30, 2026 8:00 AM EDT Company Participants Helen Rubinstein - Head of Investor RelationsPaul BernsJoshua Pinto - PresidentDaljit Aurora - Chief Operationg & Development officerNicholas Brandon - Chief Scientific OfficerMichael Milligan - CFO & Principal Accounting Officer Conference Call Participants Myles Minter - William Blair & Company L.L.C., Research DivisionBrian Abrahams - RBC Capital Markets, Research DivisionDouglas Tsao - H.C. Wainwright & Co, LLC, Research DivisionAlyssa Larios - Leerink Partners LLC, Research DivisionJulian Pino - Stifel, Nicolaus & Company, Incorporated, Research DivisionMaddalena Delma Caiati - Guggenheim Securities, LLC, Research DivisionPoorna Kannan - Needham & Company, LLC, Research DivisionGraig Suvannavejh - Mizuho Securities USA LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the call over to Helen Rubinstein, Vice President of Investor Relations and Corporate Strategy at Neumora. Please go ahead. Helen RubinsteinHead of Investor Relations Good afternoon, and thank you for joining Neumora Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. Before we begin, I encourage everyone to visit the Investors and Media section of our website at neumoratx.com, where you can find the press release related to today's call. With me on the call today are Chief Executive Officer, Paul Berns; President, Josh Pinto; Chief Operating and Development Officer, Bill Aurora; Chief Scientific Officer, Nick Brandon; and Chief Financial Officer, Mike Milligan. I'd like to point out that we will be making forward-looking statements during today's call, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.